Zacks Investment Research downgraded DBV Technologies SA – ADR (NASDAQ:DBVT) to Hold in a statement released earlier today.
- Updated: March 20, 2017
Yesterday DBV Technologies SA – ADR (NASDAQ:DBVT) traded 1.55% higher at $34.88. DBV Technologies SA – ADR’s 50-day average is $35.33 and its two hundred day average is $35.61. The last stock price is down -0.55% from the 200-day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Trading volume was up over the average, with 103,040 shares of DBVT changing hands over the typical 78,500
Zacks Investment Research has downgraded DBV Technologies SA – ADR (NASDAQ:DBVT) to Hold in a report released on Monday March 20, 2017.
See Chart Below
DBV Technologies SA – ADR has with a one year low of $27.02 and a one year high of $37.98 and has a total market value of $0.
A total of 7 firms have reported on the stock. 4 brokerages rating the stock a strong buy, 3 brokers rating the stock a buy, 0 brokers rating the company a hold, zero analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $53.50.
More About DBV Technologies SA – ADR (NASDAQ:DBVT)
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.